Jean‐Marc Limacher

Author

Jean‐Marc Limacher

Also Known As

Annick Rossi, J M Limacher, J. Limacher, J.-M. Limacher, J.M. Limacher, Jean-Marc LIMACHER, Jean-Marc Limacher, Jean‐Marc Limacher, Jean–Marc Limacher, Julien Levang

Publications

2.8K

Citations

H-Index

Concepts

All Affiliations

Transgene (France)Inserm Hôpitaux Universitaires de Strasbourg Université Paris Cité Institut Gustave Roussy

About

Jean‐Marc Limacher is an author at Transgene (France) specializing in medicine, immunology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	19	1.4K
2	Public Health	2	2	44
3	Engineering	1	1	184
4	Biostatistics	1	1	29
5	Epidemiology	1	1	15

Jean‐Marc Limacher

Publications

Citations

H-Index

Page 1

	Year	Citations
Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial Élisabeth Quoix, Rodryg Ramlau, Virginie Westeel, The Lancet Oncology VaccinationFirst-line ChemotherapyControlled Phase 2BMedicineImmunology	2011	264
A Phase II Study of Tg4010 (Mva-Muc1-Il2) in Association with Chemotherapy in Patients with Stage III/IV Non-small Cell Lung Cancer Rodryg Ramlau, Élisabeth Quoix, Janusz Rolski, Journal of Thoracic Oncology Cancer ImmunosurveillanceMedicineImmunologyPhase Ii StudyBronchial Neoplasm	2008	202
Detection of exon deletions and duplications of the mismatch repair genes in hereditary nonpolyposis colorectal cancer families using multiplex polymerase chain reaction of short fluorescent fragments. F. Charbonnier, Grégory Raux, Qing Wang, PubMed EngineeringGeneticsPathologyShort Fluorescent FragmentsDisease Gene Identification	2000	184
Two metachronous tumors in the radiotherapy fields of a patient with Li‐Fraumeni syndrome Jean‐Marc Limacher, Thierry Frébourg, Shanti Natarajan‐Amé, International Journal of Cancer	2001	145
Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE) Markus Moehler, Jeong Heo, H.C. Lee, OncoImmunology	2019	125
A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings Stéphane Oudard, Olivier Rixe, Benoit Beuselinck, Cancer Immunology Immunotherapy VaccinationCancer ImmunosurveillanceGenitourinary CancerImmunologyTumor Immunity	2010	102
The human tumour suppressor gene p53 is alternatively spliced in normal cells. Jean‐Michel Flaman, François Waridel, Anne Estreicher, PubMed	1996	100
Trial Watch: Jonathan Pol, Norma Bloy, Florine Obrist, OncoImmunology Cancer ImmunosurveillanceOncological IndicationsOncolytic VirusesImmunologyOncolytic Virotherapy	2014	91
A Poxvirus Vaccine Is Safe, Induces T-Cell Responses, and Decreases Viral Load in Patients With Chronic Hepatitis C François Habersetzer, Géraldine Honnet, Christine Bain, Gastroenterology VaccinationViral LoadViral PersistenceHepatitis CT-cell Responses	2011	86
MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure Robert Dreicer, Walter M. Stadler, F. R. Ahmann, Investigational New Drugs UrologyCancer ImmunosurveillanceMedicineImmunologyTumor Immunity	2008	80

Page 1